PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: PIPELINE ANALYSIS
• Pain management pipeline

PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY PAIN TYPES
• Segmentation by pain types
• Nociceptive pain
• Neuropathic pain
• Psychogenic pain

PART 09: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Opioids – Market size and forecast 2017-2022
• NSAIDs – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by product

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Increase in prevalence of pain associated with chronic diseases
• Significant increase in the use of opioids for pain management
• Novel drug delivery systems and novel targets for pain management

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Endo Pharmaceuticals
• GlaxoSmithKline
• Johnson & Johnson
• Pfizer

PART 17: APPENDIX
• List of abbreviations

PART 18: EXPLORE TECHNAVIO
Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pain management pipeline 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global pain management drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global pain management drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global pain management drugs market by product – Market share 2017-2022 (%)
Exhibit 20: Comparison by product
Exhibit 21: Opioids – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Opioids – Year-over-year growth 2018-2022 (%)
Exhibit 23: NSAIDs – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: NSAIDs – Year-over-year growth 2018-2022 (%)
Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Selected current other types of drugs for neuropathic pain
Exhibit 27: Others – Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Global pain management drugs market by geography – Market share 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 39: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Market opportunity
Exhibit 42: Increasing geriatric population in Europe
Exhibit 43: Percentage of older Americans experiencing chronic pain conditions 2014
Exhibit 44: Some of the recently approved drugs by the US FDA for pain management
Exhibit 45: Some of the novel abuse-deterrent opioids and monoclonal antibodies
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: ?Endo Pharmaceuticals: An overview
Exhibit 52: ?Endo Pharmaceuticals – Business segments
Exhibit 53: ?Endo Pharmaceuticals – Organizational developments
Exhibit 54: ?Endo Pharmaceuticals – Segment focus
Exhibit 55: Endo Pharmaceuticals – Key offerings
Exhibit 56: GlaxoSmithKline: An overview
Exhibit 57: GlaxoSmithKline – Business segments
Exhibit 58: GlaxoSmithKline – Organizational developments
Exhibit 59: GlaxoSmithKline – Geographic focus
Exhibit 60: GlaxoSmithKline – Key offerings
Exhibit 61: Johnson & Johnson: An overview
Exhibit 62: Johnson & Johnson – Business segments
Exhibit 63: Johnson & Johnson – Organizational developments
Exhibit 64: Johnson & Johnson – Geographic focus
Exhibit 65: Johnson & Johnson – Segment focus
Exhibit 66: Johnson & Johnson – Key offerings
Exhibit 67: ?Pfizer: An overview
Exhibit 68: Pfizer – Business segments
Exhibit 69: ?Pfizer – Organizational developments
Exhibit 70: Pfizer – Geographic focus
Exhibit 71: ?Pfizer – Segment focus
Exhibit 72: ?Pfizer – Key offerings

Companies Mentioned
. Endo Pharmaceuticals
. GlaxoSmithKline
. Johnson & Johnson
. Pfizer